Clinical trials: Major Depressive Disorder, completed
Major Depressive Disorder
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.
- Trial name
- NCT05537584
- Testing
- Sertraline, Bupropion
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Mclean Hospital
Borderline Personality Disorder, Major Depressive Disorder
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
- Trial name
- NCT05399498
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Major Depressive Disorder, Healthy Controls
Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets
The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs.
- Trial name
- UNIKET (NCT05046184)
- Testing
- Ketamine Hydrochloride, Midazolam injection
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Closed-loop Optimized rTMS for Depression
Targeted and individualized treatments for mental health disorders are critically needed. Repetitive transcranial magnetic stimulation (rTMS) represents the front-line of new and innovative approaches to normalizing dysfunctional…
- Trial name
- NCT04142320
- Testing
- Neuronavigated rTMS
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Depression, Major Depressive Disorder
Hyperthermic Yoga for Depressive Symptoms
Study is a randomized controlled trial to assess the feasibility, acceptability, efficacy, and mechanisms of action of hyperthermic yoga versus a waitlist control for 80 medically healthy adults with mild to moderate depressive…
- Trial name
- NCT02607514
- Testing
- hyperthermic yoga
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
- Trial name
- NCT06126497
- Testing
- Ropanicant
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Suven Life Sciences Limited
Major Depressive Disorder
CBT+ for Depression
This study investigates the effects of a novel intervention approach, intentionally sequencing aerobic exercise immediately prior to therapy sessions (i.e., cognitive behavioral therapy [CBT]) to determine its effects on both…
- Trial name
- CBT+ (NCT06001346)
- Testing
- ActiveCBT, CalmCBT
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Wisconsin, Madison
Depressive Disorder, Major, Depression
Individualized Functional Connectivity Targeting in aiTBS for Depression
The goal of this clinical trial is to estimate the importance of neuroimaging in accelerated intermittent theta burst stimulation (aiTBS) for depression.
- Conditions
- Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder
- Trial name
- AINT (NCT05680727)
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Depressive Disorder, Major
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study.
- Trial name
- NCT04937829
- Testing
- 5 mg BI 1569912, 20 mg BI 1569912
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression
This study will identify the sex-dependent impact of expiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry and associated physiology in major depressive disorder (MDD).
- Trial name
- tVNS_MDD_Sex (NCT04448327)
- Testing
- active tVNS
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression
Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being.
- Trial name
- NCT05224063
- Testing
- Neuronavigated rTMS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Treatment Resistant Major Depressive Disorder
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy…
- Trial name
- ASCERTAINTRD (NCT02977299)
- Testing
- Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
- Where
- 13 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Deep Brain Stimulation for Treatment Resistant Depression
The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant…
- Trial name
- NCT00367003
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Major Depressive Disorder, Social Anxiety Disorder
Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response
Many patients with Major Depressive Disorder (MDD) and generalized Social Anxiety Disorder (gSAD) are treated with cognitive behavioral therapy (CBT) but few have meaningful improvement.
- Trial name
- NCT03175068
- Testing
- CBT, ST
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Major Depressive Disorder
HypErthermia as an Additional Treatment for the Biology and Experience of Depression
This single-arm feasibility trial administered up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions to adults aged 18 years or…
- Trial name
- HEATBED (NCT05041361)
- Testing
- Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia (WBH)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder, Depression
HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
This randomized two-arm intervention trial administers 8 weekly cognitive behavioral therapy (CBT) sessions and 4 bi-weekly active whole-body hyperthermia (active WBH) sessions or 4 bi-weekly sham WBH sessions to adults aged 18…
- Trial name
- HEATBED2 (NCT05708976)
- Testing
- Cognitive Behavioral Therapy (CBT), Active Whole-Body Hyperthermia (Active WBH)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder
Opiate Suicide Study in Patients With Major Depression
To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately…
- Trial name
- AFSP (NCT04116528)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
- Trial name
- NCT06558344
- Testing
- 5 mg BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Where
- 41 sites in United States, Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim